Study of ADCE-B05 Antibody-Drug Conjugate for Safety and Dose in Adults with Advanced Solid Tumors Receiving Intravenous Treatment Every 3 Weeks

What this Trial Is About

Researchers are studying ADCE-B05, an antibody-drug conjugate, in adults with advanced solid tumors that are difficult to treat or resistant to standard therapies. This early-phase trial aims to find the highest safe dose and recommended dose for further study, while closely monitoring safety and how the drug affects tumor growth and patient health. Participants receive ADCE-B05 through intravenous infusions every three weeks. The trial includes a dose escalation phase to identify the maximum tolerated dose, followed by a dose expansion phase to assess safety and tumor response across different dose levels. Treatment cycles continue as determined by the study protocol. During the study, participants will undergo regular evaluations including tumor scans to measure response, blood tests to monitor drug levels and side effects, and assessments of overall health and performance status. The primary goals are to assess safety, tolerability, and how the drug is processed in the body, with the study expected to last about 18 months from enrollment to completion.

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors